Southeast Asia might be becoming one of the most promising regions for the growth of DNA-based wellness platforms. As healthcare shifts from treatment to prevention, the region’s growing middle class is increasingly seeking personalised tools to take control of their health. Across the Asia Pacific, the genetic testing market is forecasted to grow from approximately USD 2.80 billion in 2024 to over USD 5.43 billion by 2033, reflecting rising demand for more tailored and proactive healthcare solutions.
Driving this momentum is a convergence of multiple forces. The cost of sequencing has decreased significantly over the past decade, and tools powered by AI are now capable of transforming raw DNA data into actionable health insights. In parallel, consumer wellness is evolving. In countries like Thailand, Malaysia, Indonesia and Vietnam, health is no longer just about curing illness. Consumers are placing greater value on improving their healthspan — the quality of their years, not just the number, which is contributing to the region’s broader health and wellness market expansion.
Singapore, in particular, is shaping up to be a strategic launchpad for genomics-driven wellness platforms. Its robust regulatory reputation, strong digital infrastructure and government-led ambitions to become a global AI hub by 2030 align with industry goals. However, regulation for consumer-grade DNA testing is still evolving. The Ministry of Health recently introduced a moratorium that prohibits insurers from using results from predictive genetic tests in general underwriting to protect consumer interests.
Can digital banks in the Philippines finally turn the corner to profitability?
Trust remains one of the biggest hurdles in consumer adoption. Genetic data is among the most sensitive forms of personal information, and consumers are demanding higher levels of protection. Global standards like ISO 27001 are increasingly becoming table stakes for companies handling bio-data, alongside local compliance frameworks such as Singapore’s Personal Data Protection Act (PDPA).
In this landscape, startups offering DNA-powered health and wellness insights have a genuine opportunity. But success will rely not only on innovation, but also on the ability to navigate complex regulatory environments, secure consumer trust, and create personalised solutions that speak to Southeast Asia’s diverse populations. As AI and genomics continue to converge, the region is poised to redefine how consumers think about health, prevention, and personal data.
To better understand whether this is the beginning of a revolution or just a natural progression, we speak to Cedric Lee, Founder and CEO of ConnectingDNA. The company has just officially entered the market and is looking to change our view on DNA wellness and how to rethink our own personal health moving forward.
Your own health journey was a catalyst for ConnectingDNA. How did your personal experience shape the platform’s direction and priorities?
ConnectingDNA isn’t just borne from my health journey, but it feels more like a summation of my life’s experiences as well – from losing my mom in my young adult years (I’m an only child), to my battle with eczema, to my experiences building a game development company, to 20+ years of experience in healthcare and regional work, all these have given me deep insights into the industry, the need for better health outcomes to improve society, and even consumer behaviour. ConnectingDNA was built on these premises – that people deserve more options (and smarter recommendations) for their wellbeing, and being healthy doesn’t need to be a slow slog, but one that is (1) simple-to-use, (2) intuitive, (3) personalised, (4) fun, and (5) rewarding as well.
Many founders draw from lived experiences, but scaling them into a marketplace is another challenge. How did you translate a personal breakthrough into a business model that can serve thousands?
Since I was young, I’ve always had a gift for breaking down complex information into simple concepts that people can easily understand. Throughout my career, that ability has sharpened. So this ability has given me great insights into how to build ConnectingDNA, which is a business model that doesn’t just solve multiple problems at the same time, but is profitable as well.
With ConnectingDNA, we didn’t want to be just another product. We built it as a marketplace that connects people with trusted wellness vendors, from nutritionists to fitness coaches to lifestyle experts. Our proprietary AI interprets DNA data and matches users with highly personalised programmes, making the experience truly actionable.
The model was designed for scalability from the start. Vendors can use our tools to deliver DNA-personalised services efficiently, which means they can reach more clients without compromising quality and even providing more premium personalised services. Today, with over 250 vendors already onboard, we’re seeing strong validation that this approach not only solves a meaningful problem but also works as a sustainable and profitable business model
With DNA testing adoption growing in Asia, what unique regional factors make Singapore and Southeast Asia the right launchpad for ConnectingDNA?
Singapore is the ideal launchpad for us because it sits at the crossroads of biotech, AI, and wellness innovation. The government has been very clear about its ambition to make Singapore a world leader in AI by 2030, and at the heart of AI is data, particularly bio-data, which is essential for healthcare innovation.
At the same time, across Southeast Asia, we’re seeing a fast-growing middle class that places more emphasis on health, wellness, and preventative care. People are no longer just thinking about lifespan, but also healthspan, living longer, healthier lives.
What makes Asia especially compelling is the diversity of genetic backgrounds here. It highlights the need for solutions tailored to local populations, rather than one-size-fits-all models imported from the West.
Singapore’s trusted regulatory environment, strong technology ecosystem, and healthcare focus make it the perfect base to build from, while Southeast Asia’s rising demand ensures we’re addressing a real and growing market need.
Genetic data is among the most sensitive personal information. What safeguards and certifications are you prioritising to reassure users about data privacy and trust?
We understand that genetic data is among the most sensitive forms of personal information, so we’ve made trust and privacy absolutely foundational to ConnectingDNA, not optional.
We’re currently in the process of obtaining ISO 27001 certification, which is the international gold standard for information security. Beyond that, our systems are built with government-grade protection and undergo regular penetration testing to ensure resilience against threats. One of our key investors actually provides cybersecurity services to governments, which gives us a strong advantage in building a robust security infrastructure.
Just as importantly, our business model is designed to be self-sustaining. We never sell or share user data. The data is used only to enhance user experiences and strengthen our AI capabilities, but never for monetisation. Users also maintain full control over their reports and how their information is used.
For us, data privacy isn’t just a compliance checkbox; it’s at the very core of building long-term trust with our users.
Do you see ConnectingDNA expanding into healthcare or insurance partnerships, given the potential of genetic data to influence preventative care and risk profiling?
Our current focus is firmly on wellness and preventative health, but we’re very open to collaborations, so long as they align with our mission of empowering individuals, not penalising them. Partnerships with healthcare or insurance players make sense if they help people take preventative actions and ultimately live healthier, longer lives.
In fact, we’ve already worked with several insurance agencies, giving talks to educate people on the importance of understanding early health risks so they can plan their health and finances proactively. There’s often a misconception that insurers can directly access consumer DNA data, but that’s not the case. In Singapore, for example, insurers are not allowed to use consumer-grade DNA test results. Only medical-grade tests for specific conditions, like breast cancer or Huntington’s disease, may be considered, and even then, under very strict guidelines set by the Ministry of Health.
Looking ahead, our long-term vision is to build an ecosystem where wellness, healthcare, and lifestyle connect seamlessly around personalised DNA insights, helping people not just manage illness, but truly optimise their healthspan.
As AI and genetics continue to converge, what does the next 5 years of DNA-based wellness look like, and what role will ConnectingDNA play in shaping that future?
In the next five years, we’ll see wellness move decisively from generic advice to fully personalised, DNA-driven recommendations. AI will make this shift accessible by turning complex genetic science into natural, conversational insights, without the jargon. We’re already doing this at ConnectingDNA.
For wellness vendors, coaches, and practitioners, this means they’ll be able to deliver truly personalised services at scale, something that was never possible before.
Our role at ConnectingDNA is to be a pioneer and leader in this movement: building the trust, infrastructure, and community needed to make DNA-based wellness a reality for everyone. Ultimately, our vision is to spark a global DNA wellness movement, with Singapore as its hub.